I’m The Only One With Genius DNA 64

I’m The Only One With Genius DNA chapter 64

At Avio, many scientists took turns interviewing Jessie.

Ryu Young-joon claimed to be the last to go, so Jesse met Carpentier’s spinal cord regeneration team, Chun Ji-myung’s organoid team, and Choi Myung-joon’s type 2 diabetes treatment team in order.

“Spinal regeneration is still a long way off. It is said that the mice experiment worked, but the number of experimental groups is small. Because of the nature of the study, we even need to experiment with monkeys to complete the clout.”

Carpentier said.

“Warden organoids have a lot of room for future applications in the research and treatment of Crohn’s disease and other diseases. Oh, of course, we were motivated to study, so we stayed up all night and made results. It’s finally working! I thought the organoids were a snap, but……our CEO wants to season it now. Can you give me a job notice after this interview? Almost all of our teams are dying.”

Chun Ji-myung said.

“All this success stems from our CEO’s sharp insights and intelligent ideas. We have only set various variables and conditions that arise from faithfully carrying out the basic strategy that the CEO has prepared. Just as we can get first place if we study mainly with textbooks, we developed A-Muk by following the CEO’s direction.…”

Choi Myung-joon said.

“But I heard you worked with Selizenor to develop it, so can I see the Celizenor staff?”

Jessie asked.

“I think you should go to Selizenor. They don’t do research here.”

Selizenner.

It is a venture company that has become quite popular at IUBMB. I heard that he is working with Avio on collaborative research.

“Thank you. I’m going to Selizenor.”

“But I don’t think there’s a key probiotic researcher in India right now.”

“India?”

“Yes, the IUBMB asked a good investor before, and that’s some kind of loan in India. So they went to India with CEO Selizener and the researcher to get the investment.”

“Thank you.”

“Are you going to Selizenor?”

“If you don’t have a CEO or a key researcher, I’ll have to think about it. Let’s meet the clinical trial researchers first.”

* * *

Jesse moved to Eisen.

He also visited the stem cell department and the clinical trial management center where glaucoma clinical trials were conducted and interviewed with officials.

I also met St. John, who was a glaucoma clinical trial doctor at Seonyu Hospital.

“But why did you move to Avio Hospital?”

Jessie asked during the interview.

In fact, the reason why Sung Yo-han moved was because Seonyu Hospital was at odds with Professor Ko In-guk or Professor Ryu Young-joon over the Alzheimer’s clinical trial.

There were many doctors who were disappointed with the hospital, and some doctors left Seonyu Hospital as Professor Ko In-guk, who received a lot of respect in the hospital, moved to Avio Hospital.

“I’ve wanted to move it since I first heard about building the hospital.”

Sung Yo-han said.

“But in the meantime, I had to finish the clinical trial at Seonyu Hospital, so I finished my work there.”

“It’s a shame for Seonyu Hospital. When the patients come to the hospital, they’re going to see Dr. St. John’s, the clinical trial doctor, and they’re going to Avio’s, not Seonyu’s, right?

“No matter which hospital you treat, all you have to do is get well.”

“That’s right.”

Jessie replied.

Now I’m almost done with the interview.

She returned to Avio and met Ryu Young-joon.

“Long time no see, Dr. Liu!”

She greeted me cheerfully.

“Nice to meet you.”

“How have you been? Avio’s papers fly like carpet bombs.”

“It’s all thanks to our researchers working hard on the experiment.”

Jesse had a short interview with Ryu Young-joon.

Things like how the next generation hospital will be operated in the future, and what is the fastest progress among the following research events.

“You’re distributing glaucoma treatment kits all over the world, have you heard where the treatment is going?”

“There will be news soon, right? I haven’t heard anything yet. However, India-Schmatics, a hospital supported by pharmaceutical company Schmatics, is reorganizing into a next-generation hospital, and is conducting glaucoma treatment.”

“Really?”

“Yes.”

“Yes.”

“K. You’ll hear a good news soon.”

Ryu Young-joon smiled silently as he watched Jessie, who was delighted.

After an additional half-hour interview, Jesse pulled his butt out of his seat.

“I had a great time today. I’ll call you later.”

“Jessie.”

Ryu Young-joon caught her.

“What?”

“When are you going to America?”

“Since I came all the way to Korea, I’ve used my annual leave to play and rest. I’m going back in about a week.”

“I see, and in the meantime, we might hear some important news.”

“Important news?”

Jessie shone her eyes.

“Yes, I’ve heard something, and it’s probably going to explode in a few days.”

* * *

What on earth would someone who has won all kinds of new technologies refer to as “important news”?

Jesse was even prepared to cancel his plane ticket to see it.

And Ryu Young-joon’s words are not wrong.

It was around 8 p.m. after hanging out here and there, I had a late meal at a Korean restaurant.

I was searching SNS on my cell phone because I was bored, and a news came to mind.

[Breaking news: Eye cancer occurred in patients treated for glaucoma in Nabi Mumbai, India.]

“What…

Jesse’s eyes widened.

After interviewing Ryu Young-joon for the first time, I recognized only some words in Korean that I learned little by little, but I immediately realized what the news was.

She quickly took out her cell phone, searched it a few times, and immediately called Samuel.

Jessie, isn’t it too early to call? I thought you were crying your morning alarm.

“Samuel! Watch the news now! Is the news going out in the US by any chance?”

What news?

“A glaucoma product developed by Avio has developed eye cancer in a patient treated in India!”

Excuse me?

“Schmatics is making a public announcement right now.”

-What the… -I’ll look for it right now.

“Nature will cover this as headline news. If there is a problem with glaucoma therapy, it could hurt us who first published the paper.

All right, calm down. I’ll have to watch the presentation at Schumatics first. I’ll check and let you know. Hang up.

After the call ended, Samuel immediately turned on the computer.

Luca Taylor, CEO of Schmatics, was hosting a press conference.

“As part of our international medical charity work, we are sponsoring India’s Indian Shmatics, a hospital in India. India-Schmatics bought Avio’s glaucoma treatment kit this time. Scientists and doctors in the hospital treated the patient with it. We’ve seen eye cancer in one patient, although most of them are improving.”

“Who is the scientist in the hospital talking about?”

The reporters asked.

“Schmatic stem cell experts have received resources and sent them to Avio. They learned stem cell differentiation techniques directly from CEO Ryu Young-joon at Avio and proceeded with optic nerve differentiation at Indian Schmatics.”

“There were scientists in the hospital who could conduct optic nerve differentiation?”

“That’s right. We were impressed by Avio’s growth and decided to quickly follow their breath. That’s why we put techniques in India with stem cell differentiation facilities to make it the world’s second-generation hospital.”

“Wasn’t it because of the doctor’s mistake, not the optic nerve?”

“I don’t think so. We wanted to build this hospital for humanitarian and welfare purposes. Therefore, Professor Martin, the best eye disease specialist, was brought in from France. In addition, the entire procedure was recorded on CCTV in the operating room, and there was no problem with the procedure.”

Luca Taylor said.

“And even if you make some mistakes in surgery, the tumor doesn’t suddenly multiply unless it’s irradiated. There was no other cause for cancer.”

“How’s the patient doing?”

“I’m preparing for surgery, but it’s not easy to remove due to the nature of the tumor.”

“Are you sure it’s a tumor?”

“I’m sure.”

Luca Taylor said.

Luca Taylor said.

Although he is now a businessman, he was once one of the best scientists in the world.

Luca Taylor also worked carefully on this.

He observed the progress of the tumor. The aggregation of normal cells will break down within three days.

But the tumor continued to multiply five days later.

“The tumor is constantly growing in size. Unfortunately, India’s Schmatics Hospital doesn’t have facilities to remove the patient’s eye tumor. So I’m going to move to another developed country for treatment. The longer it takes, the worse it’ll be for the patient. I’m going to hurry as much as I can.”

Luca Taylor said.

“There were no patients developing tumors in the clinical world, so why were there patients here alone?”

One of the reporters asked.

“Most of the people who took clinical trials in Korea were Koreans, right? I think that genetic background differences may have resulted in this. Anyway, what’s clear is that this technology is less proven to be available to the world.”

Luca Taylor said.

“It’s the first stem cell therapy, and it’s a technology that uses stem cells that are no different from cancer cells. You’ll have to be a lot more careful than any other new drug.”

It was when reporters were dictating his presentation and writing breaking news.

Ring.

An alarm went off on a reporter’s cell phone.

He took out his cell phone and was surprised to see the message.

“Ryu Young-joon, CEO of Avio, says he will hold a press conference in Korea now.”

“Press conference?”

You’re having a press conference over here, and you’re going to answer it right now?

The reaction is as fast as if he had been waiting.

There was a stir among the reporters.

Luca Taylor’s long-sharp sense of business was a perception of danger.

Something’s wrong.’

* * *

“The safety of Avio’s glaucoma therapy kit is now at India’s Schmatics. They said a tumor occurred in the eye of a patient who had been treated for glaucoma.”

Ryu Young-joon said in front of reporters.

She is not a reporter, but Jessie was here as well.

Click! Click!

Journalists wrote articles endlessly filming cameras.

“But it’s not a tumor.”

Ryu Young-joon said firmly.

“It’s the result of the safety device in the stem cell therapy kit working.”

“Safe?”

Journalists began to rumble.

“With Kit No. 1, the virus will attach the cell suicide gene TP54 to the end of the LOX3 gene. And because LOX3 continues to be expressed in stem cells that are not differentiated by optic nerves, TP54 comes out together and over time the cells die out. All the stem cells made in Kit 1 are in a time-limited state from that moment on.”

Ryu Young-joon said.

“This process is re-inhibited by the virus in Kit 2. As the optic nerve differentiates, the expression of LOX3 is suppressed, so TP54 is no longer available. It’s an algorithm that dies in stem cell states over time, but not in optic nerve cells. The reason why we created this system is because we were worried that microscopic amounts of stem cells would remain in the patient’s eyes and cause side effects during the treatment. I mean, it’s kind of a safeguard. So our stem cells don’t cause cancer if they enter the affected area.”

Knock, knock, knock knock!

The sound of journalists typing on laptops spread all over the place.

Reporters did not immediately follow Ryu Young-joon’s explanation, but Jessie, a scientist, understood what Ryu Young-joon was talking about. It’s really shocking.

So far, countless scientists have worked hard to make nerves out of stem cells and treat patients with them.

I couldn’t do that, so far glaucoma has been incurable.

However, Ryu Young-joon not only conquered the stage but also took a step further.

Now, it has eliminated the side effects that are triggered by the possibility of extreme evil.

This works?

She was ecstatic as if she were drunk on religion.

When everyone raved about the technology as an innovative step forward, Ryu Young-joon was not satisfied and moved forward with his research.

“Not making progress is not stagnation, but regression.’

When I was interviewing Ryu Young-joon in the past, I remembered what he said. I got goosebumps.

Ryu Young-joon said.

“So what’s the tumor in the patient’s eye? If stem cells enter the patient’s eyes in trace amounts, the process of extinction is not observed because they are too small. However, if you enter in large quantities, the stem cells are aggregated over time to form mass cells. It looks like a tumor on the surface. That’s what Luca Taylor thought was cancer.”

“So what’s the tumor in the patient’s eye? If stem cells enter the patient’s eyes in trace amounts, the process of extinction is not observed because they are too small. However, if you enter in large quantities, the stem cells are aggregated over time to form mass cells. It looks like a tumor on the surface. That’s what Luca Taylor thought was cancer.”

Ryu Young-joon’s words did not have the same honorific name as the “CEO of Schumatics.” There were no honorifics as scientists such as “Doctor” or “Doctor.”

I just called her ‘Luca Taylor’ myself.

Some reporters felt the strange aggressive nuance of the expression. I had a hunch that something bigger would come out.

“I’d rather think that it was because of Schmatics’ poor performance. I want to believe that even though scientists there were educated at Avio, they couldn’t experiment with the kit products being made and fed up with them.”

Ryu Young-joon said.

“But it wasn’t. I shared a report that the U.S. Intelligence Department reported to the U.S. President a few days ago.”

Ryu Young-joon looked at the printed file.

“There’s a situation here where Luca Taylor directs her to administer stem cells, not optic nerves, directly to the patient’s eyes. In the patient’s eyes, it was deliberately intended to cause cancer.”

“Ah……”

“Ugh……”

Short sighs of acupuncture and dismay spread among journalists.

They were quickly thrown into great confusion. Among the buzzing noises, Ryu Young-joon said.

“We’ll have to thoroughly investigate what kind of dirty ruse and purpose this was for.”

“Mr. Ryu! Is everything you just said true?”

One of the reporters shouted.

“If there’s any lie in what you’ve said, I’ll resign as CEO of Avio.”

Ryu Young-joon had precipitation.

Once again, shocked reporters took pictures one after another.

Ryu Young-joon said.

“Safety devices follow not the usual apoptosis mechanism, but the artificial apoptosis mechanism by TP54. This process is about two weeks slower than normal agitation apoptosis, but much safer as it decomposes slowly.”

“…….”

“The next two weeks. Watch. The tumor that Luca Taylor talked about will disappear from the patient’s eyes. Please watch that the power of true science is far superior to their wickedness, as mean people who deceive medicine deliberately try to make cancer.”

A text message came from Jessie’s cell phone.

It was Samuel.

A White House spokesman is announcing now in the US government. About Luca Teral and the Duke of Schmatics.]

A White House spokesman is announcing now in the US government. About Luca Teral and the Duke of Schmatics.]

I’m The Only One With Genius DNA chapter 64

|

ToC

|